Skip to main content

Table 2 Patient baseline characteristics by LPA16:0 subgroups

From: Lysophosphatidic acid species are associated with exacerbation in chronic obstructive pulmonary disease

LPA16:0 Low
N = 45
Medium
N = 46
High
N = 45
p value
LPA16:0 tertile concentration (µM)
 Male  < 0.12 0.12 to < 0.20  ≥ 0.20  
 Female  < 0.18 0.18 to < 0.30  ≥ 0.30  
 Age (years) 61.3 (7.6) 67 (6.6)* 65.3 (6.6)* 0.00052
 Body mass index 27.6 (5.3) 25.3 (4.7) 28.5 (5)+ 0.0069
 Former smokers, % 24 (53) 29 (63) 23 (51) 0.47
Post-bronchodilator FEV1
 Absolute (L) 1.3 (0.5) 1.3 (0.5) 1.3 (0.4) 0.56
 % predicted 46.1 (17.2) 46.4 (15.8) 47.5 (12.6) 0.90
 Post-bronchodilator FEV1/FVC ratio 0.5 (0.1) 0.5 (0.1) 0.5 (0.1) 0.83
 SGRQ-C score 58.8 (17) 55.7 (16.1) 58.2 (20) 0.68
GOLD, %
 Stage II 20 (44.4) 20 (43.5) 22 (48.9)  
 Stage III 13 (28.9) 18 (39.1) 18 (40.0) 0.40
 Stage IV 12 (26.7) 8 (17.4) 5 (11.1)  
Patients with chronic bronchitis, % 39 (86.7) 34 (73.9) 34 (75.6) 0.17
Patients with severe exacerbation in previous 12 months, % 13 (28.9) 12 (26.1) 12 (26.7) 0.97
Median blood eosinophil count (cells/μL) 185 (105) 160 (97.5) 200 (265) 0.15
Median fibrinogen (g/L) 3.5 (1.1) 3.6 (1.5) 3.5 (1) 0.26
  1. Data are n (%), mean (SD), or median (IQR).
  2. *Tukey test p < 0.05 compared to LPA-low
  3. +Tukey test p < 0.05 compared to LPA-medium. FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; SGRQ-C, St. George’s Respiratory Questionnaire COPD